TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37803317

Group type: EXPERIMENTAL
Intervention: Tailored approaches to care involving trusted professionals
Number of subjects: 69

Group type: COMPARATOR
Intervention: Mainstream health services
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Investment in 'in-reach' services and tailored health care
Number of subjects: 69
Study: 37803334

Group type: EXPERIMENTAL
Intervention: Multimodal low-opioid anesthesia protocol (MLOP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine-opioid anesthesia protocol (ROP)
Number of subjects: 120
Study: 37803368

Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/G) 100/6/10 µg, two inhalations twice-daily for 6 weeks after switching from high-dose ICS/LABA.
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose inhaled corticosteroid/long-acting β-agonist (ICS/LABA) regimen prior to switching.
Number of subjects: 0
Study: 37803393

Group type: EXPERIMENTAL
Intervention: Digital CBTI hubs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insomnia care as usual (in-person or virtual)
Number of subjects: 0
Study: 37803460

Group type: EXPERIMENTAL
Intervention: Rehabkompassen® tool (intervention group, n=553)
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Usual outpatient visit (control group, n=553)
Number of subjects: 1106
Study: 37803467

Group type: EXPERIMENTAL
Intervention: Compassion and Mindfulness Intervention for RA (MITIG.RA) + Treatment as Usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study: 37803473

Group type: EXPERIMENTAL
Intervention: Expression level of placental omega-3 receptors
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Maternal and cord blood samples, placental tissue samples
Number of subjects: 100
Study: 37803523

Group type: EXPERIMENTAL
Intervention: Post-pembrolizumab VI-RADS 0-3
Number of subjects: 110
Study: 37803759

Group type: COMPARATOR
Intervention: Rope-skipping exercise (2000 jumps/week)
Number of subjects: 96

Group type: COMPARATOR
Intervention: High-fiber diet (≥20 g/d DF)
Number of subjects: 96
Study: 37804162

Group type: EXPERIMENTAL
Intervention: Resistance training using cuff weights/dumbbells at light intensity (40%-50% of maximum one repetition, 10-15 repetitions for one to three times a day) for major muscle groups of upper and lower limbs on a weekly basis.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional physical therapy group (control group).
Number of subjects: 74
Study: 37804189

Group type: EXPERIMENTAL
Intervention: Traditional cardiovascular risk factors
Number of subjects: 1814

Group type: EXPERIMENTAL
Intervention: Age and prior myocardial infarction
Number of subjects: 1814

Group type: COMPARATOR
Intervention: Lipid-lowering treatment
Number of subjects: 1814

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol levels
Number of subjects: 1814

Group type: EXPERIMENTAL
Intervention: Age, Black race, body mass index, type 2 diabetes, and smoking (pack years)
Number of subjects: 1814
Study: 37804202

Group type: EXPERIMENTAL
Intervention: Reduction of systolic blood pressure (SBP) by 11% to 20%
Number of subjects: 4071

Group type: EXPERIMENTAL
Intervention: Reduction of systolic blood pressure (SBP) by >20%
Number of subjects: 4071

Group type: EXPERIMENTAL
Intervention: Achieved SBP <130 mm Hg at day 7
Number of subjects: 4071

Group type: COMPARATOR
Intervention: Reference group of increase or no change in SBP within the first 24 hours
Number of subjects: 4071
Study: 37804258

Group type: EXPERIMENTAL
Intervention: 50-W
Number of subjects: 383

Group type: COMPARATOR
Intervention: 40-W
Number of subjects: 383
Study: 37804303

Group type: EXPERIMENTAL
Intervention: In-person, risk-tailored social needs navigation
Number of subjects: 399

Group type: COMPARATOR
Intervention: Preprinted resource guide
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 399
Study: 37804307

Group type: EXPERIMENTAL
Intervention: Aortix therapy
Number of subjects: 21
Study: 37804344

Group type: EXPERIMENTAL
Intervention: eculizumab
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: ravulizumab
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: LDH response with Hb improvements
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Hb improvements
Number of subjects: 246
Study: 37804430

Group type: EXPERIMENTAL
Intervention: Palovarotene 20 mg (whole capsule or sprinkled on food)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Palovarotene 20 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Midazolam 2 mg
Number of subjects: 23
Study: 37804473

Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1328
Study: 37804472

Group type: EXPERIMENTAL
Intervention: Guselkumab treatment
Number of subjects: 494
Study: 37804569

Group type: EXPERIMENTAL
Intervention: Degarelix + Apalutamide
Number of subjects: 89

Group type: COMPARATOR
Intervention: Degarelix + Placebo
Number of subjects: 89
Study: 37804674

Group type: EXPERIMENTAL
Intervention: Dalfampridine (10 mg twice daily) plus physiotherapy (twice a week)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dalfampridine plus physiotherapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo plus physiotherapy
Number of subjects: 8
Study: 37804715

Group type: EXPERIMENTAL
Intervention: Nocturnal sleep longer than a person's average
Number of subjects: 119

Group type: COMPARATOR
Intervention: Higher intraindividual sleep variability
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Longer average sleep duration
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Longer naps
Number of subjects: 119
Study: 37804748

Group type: EXPERIMENTAL
Intervention: Varenicline (VAR)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 500
Study: 37804765

Group type: EXPERIMENTAL
Intervention: B cell depletion therapy
Number of subjects: 99
Study: 37804858

Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart (faster aspart)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 216
Study: 37805000

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 37805024

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 30
Study: 37805216

Group type: EXPERIMENTAL
Intervention: MCED testing for cancer screening
Number of subjects: 6662
Study: 37805456

Group type: EXPERIMENTAL
Intervention: Palodent plus sectional matrix system
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Trimax as contact forming instrument
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Perform as contact forming instrument
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Contact pro as contact forming instrument
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Digital force gauge
Number of subjects: 72
Study: 37805481

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) > 10th percentile for age
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) > 50th percentile for age
Number of subjects: 693
Study: 37805486

Group type: EXPERIMENTAL
Intervention: STAIRS program + Care as Usual (CAU)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Care as Usual (CAU) + basic psychoeducation
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: STAIRS program
Number of subjects: 140
Study: 37805496

Group type: EXPERIMENTAL
Intervention: Dalpiciclib and pyrotinib
Number of subjects: 41
Study: 37805539

Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring for the first 72 hours after birth
Number of subjects: 1276

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring
Number of subjects: 1276
Study: 37805605

Group type: EXPERIMENTAL
Intervention: Thyme honey oral rinse
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 28
Study: 37806074

Group type: EXPERIMENTAL
Intervention: Standard induction chemotherapy (SIC)
Number of subjects: 10
Study: 37806075

Group type: EXPERIMENTAL
Intervention: DHA supplementation (1000 mg/day)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Total vitamin A intake
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Fructose and arachidonic acid intake
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: History of low birth weight, preterm birth, pre-eclampsia, and NICU admission
Number of subjects: 1100
Study: 37806185

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 7039

Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 7039
Study: 37806314

Group type: EXPERIMENTAL
Intervention: HU6 150 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HU6 300 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HU6 450 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HU6 (combined)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HU6
Number of subjects: 80
Study: 37806333

Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB) in the side branch
Number of subjects: 500

Group type: COMPARATOR
Intervention: Drug-eluting stent (DES) in the side branch
Number of subjects: 500
Study: 37806372

Group type: EXPERIMENTAL
Intervention: LT-02 1.6 g BID
Number of subjects: 466

Group type: COMPARATOR
Intervention: Mesalamine 500 mg TID
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466

Group type: COMPARATOR
Intervention: LT-02 0.8 g QID
Number of subjects: 466
Study: 37806620

Group type: EXPERIMENTAL
Intervention: ECPR-based approach
Number of subjects: 256

Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 256
Study: 37806650

Group type: EXPERIMENTAL
Intervention: Oxytocin plus a Cook balloon
Number of subjects: 150

Group type: COMPARATOR
Intervention: Misoprostol plus a Cook balloon
Number of subjects: 150
Study: 37806651

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nifedipine 30 mg extended-release daily
Number of subjects: 47
Study: 37806794

Group type: EXPERIMENTAL
Intervention: Soft resin trays
Number of subjects: 552

Group type: COMPARATOR
Intervention: Hard resin trays
Number of subjects: 552
Study: 37807000

Group type: EXPERIMENTAL
Intervention: Simple Linear Regression Model (SLM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed Effects Model (MEM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed Effects Model (MEM) with inter-measurement variation
Number of subjects: 0
Study: 37807004

Group type: EXPERIMENTAL
Intervention: Integrated myocardial flow reserve (iMFR) assessment
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Focally impaired perfusion
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Diffusely impaired perfusion
Number of subjects: 1044
Study: 37807032

Group type: EXPERIMENTAL
Intervention: mini percutaneous nephrolithotomy (mPNL)
Number of subjects: 48

Group type: COMPARATOR
Intervention: JJ stent placement followed by second session flexible ureterorenoscopy (f-URS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: flexible ureterorenoscopy (f-URS)
Number of subjects: 48
Study: 37807179

Group type: EXPERIMENTAL
Intervention: 2 g TXA bolus
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: 1 g bolus + 1 g/8 hours TXA infusion
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 37807937

Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 142

Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 142
Study: 37807952

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37808274

Group type: EXPERIMENTAL
Intervention: 1 mL safety syringe (SSy)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: 1 mL auto-injector (AI)
Number of subjects: 214
Study: 37808500

Group type: EXPERIMENTAL
Intervention: NMES-RT + FES
Number of subjects: 33

Group type: COMPARATOR
Intervention: PMT + FES
Number of subjects: 33
Study: 37808864

Group type: EXPERIMENTAL
Intervention: EP-3533 (type 1 collagen probe)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Excised human lung tissue with RILI
Number of subjects: 0
Study: 37808932

Group type: EXPERIMENTAL
Intervention: Irritable bowel syndrome (IBS) diagnosis according to ROME IV criteria
Number of subjects: 0
Study: 37809311

Group type: EXPERIMENTAL
Intervention: tDCS (2 mA) during CCT
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: tACS (5 Hz) during CCT
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham stimulation during CCT
Number of subjects: 59
Study: 37809334

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) phacoemulsification
Number of subjects: 74

Group type: COMPARATOR
Intervention: Nanolaser technique
Number of subjects: 74
Study: 37810529

Group type: EXPERIMENTAL
Intervention: Transition to virtual visits
Number of subjects: 1313

Group type: COMPARATOR
Intervention: In-person program delivery
Number of subjects: 1313
Study: 37810589

Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg
Number of subjects: 1282
Study: 37810620

Group type: EXPERIMENTAL
Intervention: Brain-IT training concept with Senso Flex exergaming system for 12 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18
Study: 37810917

Group type: EXPERIMENTAL
Intervention: Antioxidants (Nicotinamide riboside and Pterostilbene)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Coconut oil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Antioxidants + Coconut oil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 37810925

Group type: EXPERIMENTAL
Intervention: SNAQ food-recognition mobile application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional dietary assessment methods (food records, food frequency questionnaires, 24-hour dietary recalls)
Number of subjects: 0
Study: 37810934

Group type: EXPERIMENTAL
Intervention: Adaptation of survey questions designed for cisgender men to include TGNB participants and partners
Number of subjects: 0
Study: 37811343

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus endocrine therapy (ET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocrine therapy (ET) alone
Number of subjects: 0
Study: 37811523

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 37811525

Group type: EXPERIMENTAL
Intervention: Low-energy meal replacement plan (MRP) ~810 kcal/day
Number of subjects: 27
Study: 37811538

Group type: EXPERIMENTAL
Intervention: EORTC/NCIC study (NCT00006353)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: EF-14 (NCT00916409)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: CeTeG (NCT01149109)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Other trials (not specified)
Number of subjects: 11
Study: 37811598

Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 2007
Study: 37811634

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once daily with limertinib 160 mg (Part A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg twice daily with limertinib 80 mg (Part B)
Number of subjects: 48
Study: 37811665

Group type: COMPARATOR
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 3973
Study: 37811711

Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 7014

Group type: COMPARATOR
Intervention: Neurohormones
Number of subjects: 7014

Group type: COMPARATOR
Intervention: ADHD-related medications
Number of subjects: 7014

Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 7014
Study: 37811993

Group type: EXPERIMENTAL
Intervention: Ad26 mosaic vaccine regimen
Number of subjects: 0
Study: 37812227

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37812229

Group type: EXPERIMENTAL
Intervention: Symptom questionnaire (Patient Symptom Survey)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Analgesic administration
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Sepsis diagnosis
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Being mechanically ventilated
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Family visits
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 353
Study: 37812242

Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia (VAP)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Ventilator-associated tracheobronchitis (VAT)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Hospital-acquired pneumonia (HAP)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: ICU hospital-acquired pneumonia (ICU-HAP)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Ventilator-associated HAP (VHAP)
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Overall mortality rates
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Microbiological identification
Number of subjects: 1060
Study: 37812272

Group type: EXPERIMENTAL
Intervention: Trauma Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Psychosocial Counseling (PC+)
Number of subjects: 610
Study: 37812306

Group type: EXPERIMENTAL
Intervention: Active use of PROs with built-in alert-algorithm (Intervention Arm - IA)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard procedure for handling of side effects (Control Arm - CA)
Number of subjects: 228
Study: 37812307

Group type: EXPERIMENTAL
Intervention: Balanced salt solution (BSS) supplementation before intraocular lens (IOL) implantation and before the end of surgery.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (normal AL)
Number of subjects: 95
Study: 37812381

Group type: COMPARATOR
Intervention: Prophylactic norepinephrine 0 µg/kg/min
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Prophylactic norepinephrine 0.025 µg/kg/min
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Prophylactic norepinephrine 0.05 µg/kg/min
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Prophylactic norepinephrine 0.075 µg/kg/min
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Prophylactic norepinephrine 0.1 µg/kg/min
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Prophylactic norepinephrine (all dosages)
Number of subjects: 175
Study: 37812429

Group type: EXPERIMENTAL
Intervention: XEN1101 25 mg
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: XEN1101 20 mg
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: XEN1101 10 mg
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 37812476

Group type: EXPERIMENTAL
Intervention: PELA/BZ/Dex
Number of subjects: 14
Study: 37812518

Group type: EXPERIMENTAL
Intervention: 131I-MIP-1095 (50 mCi in cohort 1, 75 mCi in cohort 2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 131I-MIP-1095
Number of subjects: 9
Study: 37812653

Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator (ICD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no ICD or CRT)
Number of subjects: 0
Study: 37812679

Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg plus ADT and docetaxel
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo plus ADT and docetaxel
Number of subjects: 54
Study: 37812772

Group type: EXPERIMENTAL
Intervention: Aroxybutynin and Atomoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37813304

Group type: EXPERIMENTAL
Intervention: Continuous oxytocin infusion (16 hours, with a 4 hours pause in between infusions)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Continuous oxytocin infusion
Number of subjects: 153
Study: 37813418

Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment started within 24-48 hours aimed at reducing systolic blood pressure by 10%-20% within the first 24 hours and achieving mean blood pressure <140/90 mm Hg within seven days.
Number of subjects: 4810

Group type: COMPARATOR
Intervention: Delayed antihypertensive treatment starting on day 8 aimed at achieving mean blood pressure <140/90 mm Hg.
Number of subjects: 4810

Group type: EXPERIMENTAL
Intervention: Early treatment group
Number of subjects: 4810

Group type: COMPARATOR
Intervention: Delayed treatment group
Number of subjects: 4810
Study: 37813479

Group type: COMPARATOR
Intervention: Vaginal brachytherapy
Number of subjects: 294

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 294
Study: 37813527

Group type: EXPERIMENTAL
Intervention: Wearable motion-based platform for functional assessments
Number of subjects: 100
Study: 37813532

Group type: EXPERIMENTAL
Intervention: Cigarette smoking status (smokers vs non-smokers)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Luminex xMAP-based multiplex immunoassay for inflammatory mediators and cytokines
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Lung function measurements and chest CT examinations
Number of subjects: 400
Study: 37813562

Group type: EXPERIMENTAL
Intervention: Cognitively impaired group (Montreal Cognitive Assessment score <26)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Normal cognition group (Montreal Cognitive Assessment score ≥26)
Number of subjects: 239
Study: 37813560

Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAAC)
Number of subjects: 1053
Study: 37813745

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 720
Study: 37813841

Group type: EXPERIMENTAL
Intervention: High-fat diet (n=73)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (n=72)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Fat-responders receiving high-carbohydrate diet
Number of subjects: 145

Group type: COMPARATOR
Intervention: Carbohydrate-responders receiving high-fat diet
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Carbohydrate-responders receiving high-carbohydrate diet
Number of subjects: 145
Study: 37813884

Group type: EXPERIMENTAL
Intervention: Dry immersion for 5 days
Number of subjects: 18
Study: 37813959

Group type: EXPERIMENTAL
Intervention: Dinutuximab beta (continuous infusion over 10 days of each cycle, for up to five cycles)
Number of subjects: 40